JBIO
Price
$19.75
Change
-$0.25 (-1.25%)
Updated
Jul 31 closing price
Capitalization
1.2B
15 days until earnings call
Intraday BUY SELL Signals
OCS
Price
$11.31
Change
+$0.10 (+0.89%)
Updated
Jul 31 closing price
Capitalization
682.99M
4 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JBIO vs OCS

JBIO vs OCS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JBIO vs. OCS commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a Hold and OCS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (JBIO: $19.75 vs. OCS: $11.31)
Brand notoriety: JBIO and OCS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JBIO: 34% vs. OCS: 14%
Market capitalization -- JBIO: $1.2B vs. OCS: $682.99M
JBIO [@Biotechnology] is valued at $1.2B. OCS’s [@Biotechnology] market capitalization is $682.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JBIO’s FA Score shows that 1 FA rating(s) are green whileOCS’s FA Score has 0 green FA rating(s).

  • JBIO’s FA Score: 1 green, 4 red.
  • OCS’s FA Score: 0 green, 5 red.
According to our system of comparison, JBIO is a better buy in the long-term than OCS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JBIO’s TA Score shows that 3 TA indicator(s) are bullish while OCS’s TA Score has 4 bullish TA indicator(s).

  • JBIO’s TA Score: 3 bullish, 5 bearish.
  • OCS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, OCS is a better buy in the short-term than JBIO.

Price Growth

JBIO (@Biotechnology) experienced а -1.64% price change this week, while OCS (@Biotechnology) price change was +1.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

JBIO is expected to report earnings on Aug 17, 2026.

OCS is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JBIO($1.2B) has a higher market cap than OCS($683M). JBIO YTD gains are higher at: 27.997 vs. OCS (-43.365). OCS has higher annual earnings (EBITDA): -93.55M vs. JBIO (-133.57M). JBIO has more cash in the bank: 311M vs. OCS (222M). JBIO has less debt than OCS: JBIO (679K) vs OCS (2.25M). JBIO (0) and OCS (0) have equivalent revenues.
JBIOOCSJBIO / OCS
Capitalization1.2B683M176%
EBITDA-133.57M-93.55M143%
Gain YTD27.997-43.365-65%
P/E RatioN/A63.08-
Revenue00-
Total Cash311M222M140%
Total Debt679K2.25M30%
TECHNICAL ANALYSIS
Technical Analysis
JBIOOCS
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
65%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
50%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
56%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
53%
Advances
ODDS (%)
Bullish Trend 19 days ago
82%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 7 days ago
62%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
JBIO
Daily Signal:
Gain/Loss:
OCS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EHSTX31.460.21
+0.67%
Eaton Vance Large-Cap Value A
LAMCX26.390.14
+0.53%
Lord Abbett Dividend Growth C
ABVCX22.210.04
+0.18%
AB Large Cap Value C
WSHFX67.53-0.02
-0.03%
American Funds Washington Mutual F-1
TGVOX31.73-0.37
-1.15%
TCW Relative Value Mid Cap I

OCS and

Correlation & Price change

A.I.dvisor tells us that OCS and JSPR have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OCS and JSPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
+0.89%
JSPR - OCS
33%
Poorly correlated
+1.48%
FTH - OCS
32%
Poorly correlated
-5.48%
GRI - OCS
30%
Poorly correlated
-2.84%
PRAX - OCS
29%
Poorly correlated
+0.03%
JBIO - OCS
28%
Poorly correlated
-1.25%
More